Ms Tara Sharpe United Kingdom

Novozymes Biopharma develops and manufactures sustainable, safe, biological based ingredients and technologies to provide pharmaceutical and medical device manufacturers the knowledge-based solutions needed to address the challenges in developing innovative, safer, and more consistent final products. The company's large-scale manufacturing facilities worldwide are run to cGMP Q7 quality standards to ensure that customers receive the highest level of product quality and consistency, as well as the security of long-term supply. Novozymes’ customer-integrated approach combines the company’s scientific know-how and the specific needs of customers to deliver improved products and performance. By combining Novozymes’ unique knowledge around our biological solutions such as recombinant albuminhalf-life extension and hyaluronic acid with the specific application knowledge of our customers, we work with companies to deliver improved performance and safety for next generation of medical device and pharmaceutical products.
Novozymes Biopharma UK
LinkedIn logo Business Development Manager 

Dr Sahar Shepperd

Bristows is a law firm dedicated to serving businesses with interests in intellectual property and technology, in industry sectors ranging from pharmaceuticals, electronics,IT and telecommunications to consumer products, television and entertainment.

Bristows LLP
Associate 

Dr Dimitris Sideris

The company develops companion diagnostic tests and biomarker discovery platforms based on its unique analytical technology, the CycloChipTM. The tests come in the form of disposable cartridges specific to desired applications. 

Direct comparative studies, have shown that the technology is between 30x-270x times faster, with over 10x higher resolution and 2000x more sensitive than competing top of the range analytical instruments.

The fact that this performance can be achieved in disposable devices that can be flexibly customised to different diagnostic and analytical applications, makes this device very attractive diagnostic companies and CROs.

GMD is looking for end-users of the technology to tailor the disposable cartridges to their specific needs. 

The CycloChipTM performs the tests based on a unique molecular separation method that allows for unprecedented throughput, sensitivity and resolution. Unlike chemistry based diagnostic companions, our system is not limited to a single molecule or a small number of molecules, but rather it can be tailored to an endless number of different molecular tests, tailored to the needs of our pharmaceutical or diagnostic client.

The GMD system can be applied to both proteomic and genomic analyses.

GMD is looking for a partner/end user to out license its technology and at the same time develop its product portfolio driven by the specific needs of the end-user. The latter could be a pharmaceutical company with internal R&D or a diagnostic company. 

GMD is based at Kingston University, London. It's technology has been awarded multiple prestigeous grants, from the London Development Agency and Technology Strategy Board.

Genetic Microdevices
Chief Executive Officer 

Dr David Simpson United Kingdom

Glythera is an emerging biotechnology company specializing in the development of next generation biotherapeutics through the application of its advanced proprietary conjugation and glycosylation technologies.

Located in the North East of the UK with its dedicated bioprocessing and chemistry development laboratories at Newcastle University, Glythera is positioned as a critical partner in any development program centred on its PermaLink™ and PermaCarb™ technologies.

Our PermaLink™ platform supports highly selective site specific conjugation whilst demonstrating significantly increased stability with our core focus being in the development of enhanced Antibody Drug Conjugates and bi-specifics.

Glythera’s PermaCarb™ technology allows direct substitution of endogenous glycan’s or correction of micro-heterogeneity using stable analogues to improve bioavailability and efficacy and has been demonstrated in a range of next generation biotherapeutics.

Our Mission is to enable improved clinical regimes through the creation of the next generation of safe, efficacious biotherapeutic products in oncology and therapeutic indications.

 

Website:
www.glythera.com
Company type
Glythera Ltd
Chief Operating Officer 

Mr Raymond Spencer United Kingdom

MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise.

Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens. Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.

MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections.

MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.

Company type
MGB Biopharma

Dr Alasdair Stamps United Kingdom

BioPartner is your UK point of contact at Bio-Europe 2013 based at stand #68.

BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. Through the BioPartnership Programme, BioPartner assists companies to attend major international biopharma conferences by providing access to government grants and heavily discounted entry fees.

Company type
BioPartner UK
Executive Director 

Mr Ian Trelfa United States

Albany Molecular Research, Inc. (AMRI)


For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCINGTM, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline.
AMRI (NASDAQ: AMRI), provides scientific services, technologies and products focused to the pharmaceutical industry since 1991. The Company’s core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing services.

AMRI
Business Development Manager 

Mr Matthew Warren

Bristows is a law firm dedicated to serving businesses with interests in intellectual property and technology, in industry sectors ranging from pharmaceuticals, electronics,IT and telecommunications to consumer products, television and entertainment.

Bristows LLP
Partner